buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
Company Atlas/HealthCare/Glenmark Pharmaceuticals
NSE: GLENMARK· HealthCareValue · Aug 26Mid cap

Glenmark Pharmaceuticals

Turnaround: net cash, innovation royalties

Last close
₹2,441.50
29 Sept 2026 · reference
1D · 1M
+5.0% · −2.9%
price-only
Weight
2.4%
31 Jul 2026 · Aug rank 11
Thesis review
8 Sep 2026
Why We Own, p41
Coverage owner: Research (per book); latest results Q Jun-26Buoyant AIF I Top 30 Holdings - Aug 2026.pdf · p1Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026) · p41Screener ↗Tijori ↗NSE ↗
OverviewBusiness & segmentsChartsFinancialsValuationThesisRisks & catalystsCompetitorsResearch & documents
Broker research · 1 report

Sell-side views, extracted from the PDFs on file

ICICI SecuritiesHOLDresult update
Glenmark Pharmaceuticals: Growth accelerates across regions; profitability yet to catch up
4 Aug 2026 · Abdulkader Puranwala, Nisha Shetty, Darshil Jain · 12 pp · open PDF ↗
Target
₹2,100
At report
₹2,230−6% printed
Vs our close
−14.0%

ICICI Securities maintains HOLD on Glenmark Pharmaceuticals after Q1FY27 revenue beat estimates (up 18% YoY ex out-licensing income) on strong India, US and emerging-market growth, but EBITDA and profits lagged as gross/EBITDA margins contracted ~122bps/119bps YoY on raw material cost pressure. The broker keeps its TP unchanged at INR2,100 (20x FY28E EPS plus INR225 NPV for NCE pipeline), citing management's reiterated FY27 EBITDA margin guidance of 21-22% and out-licensing of ISB 2301 as a key near-term trigger, while flagging that margin recovery has yet to catch up with the revenue momentum.

Thesis
  • Revenue grew 18% YoY (ex USD17.5mn Abbvie licensing income) to INR38.5bn, ahead of I-Sec's INR35.8bn estimate, driven by India (+15.5% YoY), US (+8.5% YoY, +19.8% ex out-licensing) and emerging markets (+27.7% YoY)
  • India business grew 15.5% YoY to INR14.3bn on strong dermatology, respiratory, cardiology and oncology traction; broker expects India to grow at 21.8% CAGR over FY26-28E
  • US business expected to accelerate at 15.3% CAGR over FY26-28E, aided by gFlovent launch, Monroe plant relaunches and upcoming differentiated injectables contributing meaningfully from FY28
  • Gross margin contracted 122bps YoY to 67.7% and EBITDA margin fell 119bps YoY to 16.6% (vs I-Sec estimate of 18.4%) on raw material cost pressure and higher overheads
  • Management reiterated FY27 EBITDA margin guidance of 21-22%, expecting improvement via better product mix and operating leverage
  • ISB 2301 IND application planned for filing in CY26 with trials starting CY27; out-licensing of this molecule seen as a key near-term trigger, similar to the prior ISB 2001 deal with Abbvie
Risks
  • Delay in ramp-up of key products
  • Higher-than-expected cash burn in the Innovative Global Institute (IGI) biologics business
  • Elevated API prices, logistics disruptions and higher operating expenses could dent margins near term
  • Europe regional growth was muted in the quarter (constant currency growth of only 1.2%)
Q1FY27 highlights
  • Net Sales INR38,531mn, up 18.0% YoY (up 6.6% QoQ)
  • Gross margin 67.7%, down 122bps YoY
  • EBITDA INR6,394mn, up 10.1% YoY; EBITDA margin 16.6%, down 119bps YoY
  • Adjusted PAT INR3,688mn, up 17.9% YoY (down 18.5% QoQ)
  • India revenue INR14,321mn, up 15.5% YoY (up 40.4% QoQ)
  • US sales USD99mn, up 8.5% YoY (up 17.3% QoQ); RoW revenue up 27.7% YoY
Catalysts
  • Out-licensing of ISB 2301 molecule following IND filing in CY26
  • Additional respiratory launches and differentiated injectables from the Monroe plant
  • Ryaltris launch in Brazil (H2FY27) and expansion to 10 more countries; QiNHAYO commercial launch expected FY28
  • Faster-than-expected recovery in the US business
Broker estimatesUnitFY25AFY26AFY27EFY28E
Net Revenue₹ mn1,33,2171,30,0081,58,7481,72,686
EBITDA₹ mn23,73410,72229,08034,548
EBITDA Margin%17.88.218.320
Net Profit₹ mn13,8945,10421,05625,845
EPS₹49.218.174.691.6
P/Ex60.146.228.424.3
EV/EBITDAx26.757.620.616.7
RoCE%16.96.821.121.3
RoE%16.65.318.218.7

Valuation: 20x FY28E EPS plus NPV of INR225 for NCE (ISB) pipeline products. Broker maintains HOLD with unchanged TP of INR2,100, valuing the base pharma business at 20x FY28E EPS and adding an unchanged NPV of INR225 per share for the NCE/biologics pipeline. FY27E/FY28E EPS raised by ~4-5% (revenue estimates raised 5.5%/7.3% and EBITDA raised 1.9%/2.8% for FY27E/FY28E) while EPS itself was cut 4.9%/3.4% for FY27E/FY28E, mainly reflecting higher interest costs; TP left unchanged at INR2,100.

Extraction note: The report's own 'Earnings Revisions' table shows Revenue/EBITDA raised and EPS cut for FY27E/FY28E simultaneously (higher interest cost offsetting operating upgrades) — both effects are captured in estimateChanges. Figures are in INR mn as printed; the earnings-revisions percent…

Figures are transcribed from each broker's PDF as printed (units as the broker states them) and are the broker's estimates, not Buoyant's. "Vs our close" recomputes the target against the latest reference close (29 Sept 2026).

SWOT

Strengths · Weaknesses · Opportunities · Threats

Draft
Strengths
  • Balance-sheet turnaround is done: borrowings fell from Rs 2,473 cr (Mar-25) to Rs 594 cr (Mar-26) and management now reports gross debt zero with Rs 800-900 cr cash, after the $700 mn AbbVie upfront for ISB 2001.
  • Base business is growing faster than peers: Q1FY27 revenue +23.1% (18%+ ex deferred income) with India +15.5% vs IPM MAT growth of 10.2%; FY27 guidance is 18%+ base-business growth and 21-22% EBITDA margin vs 20.0% in Q1.
  • Free optionality on innovation: ISB 2001 (AbbVie) carries up to $1.225 bn in milestones plus tiered double-digit royalties with 160+ patients dosed in Phase 1; ISB 2301 IND expected in CY2026 and could be the next out-licensing event.
  • US respiratory pipeline is finally converting: first ANDA for fluticasone 44 mcg with 180-day exclusivity, fluticasone OTC nasal spray approved, Monroe injectables plant got a VAI EIR (Nov-2025), 53 ANDAs pending and 2-3 more respiratory approvals expected in H2FY27.
Weaknesses
  • vs Lupin: Lupin is cheaper (16.2x TTM PE, ROE 28.7%) but its FY26 earnings are inflated by US exclusivity products (gMirabegron/gTolvaptan) that roll off; Glenmark offers cleaner 18%+ base growth plus un-modelled ISB 2001 milestones.
  • vs Cipla: Cipla trades at 31.3x TTM with TTM sales +2% and profit -34% (gRevlimid loss, US pricing); Glenmark grows 23% with a net-cash balance sheet and no single-product cliff.
Opportunities
  • H2FY27: 2-3 US respiratory ANDA approvals expected (fluticasone 110 mcg, ipratropium bromide) plus gFlovent ramp from Monroe.
  • CY2026: ISB 2301 IND filing (potential second out-licensing) and any AbbVie development milestone on ISB 2001 as Phase 1 dose-expansion data matures.
  • Q2FY27 results (~early Nov-2026): first read on whether EBITDA margin is tracking the 21-22% FY27 guidance and on GLIPIQ semaglutide uptake in India.
Threats
  • FY26 earnings quality: reported FY26 EBITDA of Rs 4,572 cr (27% OPM) includes ISB 2001 licensing income; clean run-rate EBITDA margin is ~20%, so headline TTM PE of 22x understates true valuation (~32x FY27E).
  • Margin squeeze from geopolitics: management flagged API and logistics cost inflation hurting margins for 'at least 2 quarters'; Q1 gross and EBITDA margins contracted 122/119 bp ex licensing income.
  • US regulatory/launch risk: 53 pending ANDAs and the gFlovent/gFlonase ramp depend on Monroe and Indian plants staying clean; ISB 2001 milestones are binary and none have triggered yet.

Compiled from the approved one-pager (Why We Own What We Own, 8 Sep 2026): why-we-own → strengths, catalysts → opportunities, key risks → threats, peer caveats → weaknesses. Editorial mapping pending review. · author: compiled from the approved one-pager

Research reports · upload with a check step

0 approved · 0 pending · 0 rejected

Only approved reports are readable from the company page; the reviewer must differ from the uploader. Files are hashed (duplicates skipped) and held in the private store.

Internal evidence

Buoyant sources for this name

  • August 2026 top-30 disclosure — rank 11, HealthCare, Value. Buoyant AIF I Top 30 Holdings - Aug 2026.pdf
  • One-pager, "Why We Own What We Own" — p41, 8 Sep 2026. Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026)
  • Sales playbook, Aug 2026 — holdings matrix (PMS/AIF I/AIF II, $31 Jul 2026). Buoyant_Capital_Sales_Playbook_Aug_2026_Full_Holdings.pdf

Original PDFs are in the supplied package on disk; private object storage is not configured, so source pages are referenced, not served.

Company filings

Investor documents (Tijori knowledge base)

annual reports
  • Annual report FY26
  • Annual report FY25
  • Annual report FY24
  • Annual report FY23
  • Annual report FY22
  • Annual report FY21
earnings releases
  • Results Jan26
  • Results May26
  • Results Jul26
  • Results May25
  • Results Aug25
  • Results Nov25
  • Results Mar24
  • Results Jun24
  • Results Sep24
  • Results Dec24
  • Results Mar23
  • Results Jun23
investor presentations
  • Presentation Jan26
  • Presentation May26
  • Presentation Jun26
  • Presentation Jul26
  • Presentation May25
  • Presentation Jul25
  • Presentation Aug25
  • Presentation Nov25
  • Presentation Feb24
  • Presentation Mar24
  • Presentation Jun24
  • Presentation Sep24
conference calls
  • Call Feb26
  • Call Jun26
  • Call Mar25
  • Call Aug25
  • Call Nov25
  • Call Mar24
  • Call Jun24
  • Call Dec24
  • Call Mar23
  • Call Jun23
  • Call Sep23
  • Call Dec23

Links open the issuer's or exchange's document; fetched only through the user's browser, never by the platform.

Ownership

Shareholding · Jun'26

Promoter46.65%
Indian Promoters46.65%
SALDANHA FAMILY TRUST45.44%
BLANCHE ELIZABETH SALDANHA0.39%
GLENN MARIO SALDANHA0.36%
CHERYLANN MARIA PINTO0.27%
ROBIN JOSEPH PINTO0.18%
NEHA SALDANHA0.01%
Public Shareholding53.35%
Institutions39.53%
HDFC MUTUAL FUND - HDFC MID-CAP FUND6.22%
GOVERNMENT PENSION FUND GLOBAL3.89%
AMANSA HOLDINGS PRIVATE LIMITED2.22%
INVESCO INDIA CONTRA FUND2.20%